## Identification of high thrombotic risk tripleâ€positive a dependent on antiâ€eardiolipin and antiâ€Î²2glycoprot

Journal of Thrombosis and Haemostasis 16, 2016-2023 DOI: 10.1111/jth.14261

**Citation Report** 

#	Article	lF	CITATIONS
1	Curative resolution of chronic thromboembolic pulmonary hypertension with pulmonary thromboendarterectomy in primary antiphospholipid syndrome. Medicine (United States), 2018, 97, e12710.	1.0	0
2	Commentary on: Circulating plasmablasts contribute to antiphospholipid antibody production, associated with typeÂl interferon upregulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1030-1032.	3.8	2
3	Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmunity Reviews, 2019, 18, 102395.	5.8	35
5	Challenges and Advances in SLE Autoantibody Detection and Interpretation. Current Treatment Options in Rheumatology, 2019, 5, 147-167.	1.4	9
6	Laboratory Evaluation of Antiphospholipid Syndrome. Clinics in Laboratory Medicine, 2019, 39, 553-565.	1.4	6
7	The (nonâ€)sense of detecting antiâ€cardiolipin and antiâ€Î²2glycoprotein I IgM antibodies in the antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2020, 18, 169-179.	3.8	50
8	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. Rheumatology, 2020, 59, 146-152.	1.9	14
9	Detection of antiâ€domain I antibodies by chemiluminescence enables the identification of highâ€risk antiphospholipid syndrome patients: A multicenter multiplatform study. Journal of Thrombosis and Haemostasis, 2020, 18, 463-478.	3.8	20
10	Testing for antiphospholipid antibodies: Advances and best practices. International Journal of Laboratory Hematology, 2020, 42, 49-58.	1.3	22
11	How to Interpret Antiphospholipid Laboratory Tests. Current Rheumatology Reports, 2020, 22, 38.	4.7	25
12	Antiphospholipid antibodies in patients with COVIDâ€19: A relevant observation?. Journal of Thrombosis and Haemostasis, 2020, 18, 2191-2201.	3.8	143
13	Misdiagnosis of high thrombotic risk triple-positive antiphospholipid antibodies. Thrombosis Research, 2021, 197, 33-35.	1.7	1
14	Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review). Experimental and Therapeutic Medicine, 2021, 21, 287.	1.8	0
15	Thrombotic disorders in children. , 2021, , 601-634.		0
16	Challenges and Advances in SLE Autoantibody Detection and Interpretation. , 2021, , 67-91.		1
17	Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. Current Rheumatology Reports, 2021, 23, 10.	4.7	12
18	Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review. Biomedicines, 2021, 9, 166.	3.2	18
19	Systemic and organ-specific immune-related manifestations of COVID-19. Nature Reviews Rheumatology, 2021, 17, 315-332.	8.0	194

CITATION REPORT

#	Article	IF	CITATIONS
20	Deciphered coagulation profile to diagnose the antiphospholipid syndrome using artificial intelligence. Thrombosis Research, 2021, 203, 142-151.	1.7	6
21	Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort. Frontiers in Immunology, 2021, 12, 648881.	4.8	9
22	Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update. Archives of Gynecology and Obstetrics, 2021, 304, 1153-1160.	1.7	5
23	In vitro diagnostics for the medical dermatologist. Part II: Hypercoagulability tests. Journal of the American Academy of Dermatology, 2021, 85, 301-310.	1.2	2
24	Single or triple positivity for antiphospholipid antibodies in "carriers―or symptomatic patients: Untangling the knot. Journal of Thrombosis and Haemostasis, 2021, 19, 3018-3030.	3.8	9
25	A Novel ELISA Assay for the Detection of Anti-Prothrombin Antibodies in Antiphospholipid Syndrome Patients at High Risk of Thrombosis. Frontiers in Immunology, 2021, 12, 741589.	4.8	6
26	Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome. Thrombosis and Haemostasis, 2021, 121, 1220-1227.	3.4	27
27	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. Rheumatology, 2021, 60, 1114-1124.	1.9	41
28	Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. Hematology American Society of Hematology Education Program, 2019, 2019, 415-420.	2.5	5
29	Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. Journal of Translational Autoimmunity, 2021, 4, 100134.	4.0	21
30	IgG fractions from patients with antiphospholipid syndrome and systemic lupus erythematosus bind to platelets, but do not affect collagen-induced platelet activation. Biotechnic and Histochemistry, 2022, 97, 604-615.	1.3	0
31	Epidemiology of Antiphospholipid Syndrome in the General Population. Current Rheumatology Reports, 2021, 23, 85.	4.7	49
32	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatric Drugs, 2022, 24, 13-27.	3.1	5
33	Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances. Journal of Clinical Medicine, 2022, 11, 2164.	2.4	18
34	Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis, 2022, 20, 2136-2150.	3.8	18
35	Solid Phase Assays for Antiphospholipid Antibodies. Seminars in Thrombosis and Hemostasis, 2022, 48, 661-671.	2.7	11
36	Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell's viper venom time and silica clotting time increases thrombotic risk prediction. Journal of Thrombosis and Thrombolysis, 0, , .	2.1	0
37	Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome. International Journal of Molecular Sciences, 2022, 23, 8973.	4.1	2

ARTICLE IF CITATIONS # Anticoagulant Therapy in Patients with Antiphospholipid Syndrome. Journal of Clinical Medicine, 2022, 38 2.4 7 11,6984. Brainstem stroke in a patient with systemic lupus erythematosus and triple antiphospholipid antibody profile. BMJ Case Reports, 2022, 15, e254147. Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients. PLoS ONE, 40 2.5 2 2023, 18, e0279450. From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children. International Journal of Molecular Sciences, 2023, 24, 3001. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ, The, O, , e069717. 42 6.0 33 A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies. Investigational New Drugs, 2023, 41, 317-323. 2.6 Application of the thrombin generation assay in patients with antiphospholipid syndrome: A systematic 44 2.4 3 review of the literature. Frontiers in Cardiovascular Medicine, 0, 10, . Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Anti-phosphatidylserine/Prothrombin Antibodies (aPS/PT). Methods in Molecular Biology, 2023, 315-327 Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in a patient 47 with systemic lupus erythematosus and antiphospholipid syndrome: case presentation and review of 1.9 2 the literature. Hormones, 2023, 22, 521-531. Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant 3.8 assay. Journal of Thrombosis and Haemostasis, 2023, 21, 3539-3546. Pediatric antiphospholipid syndrome. Medicinski Podmladak, 2023, 74, 49-55. 49 0.0 0 Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 0, , . Exploring clinical indicator variations in stroke patients with multiple risk factors: focus on 51 2.2 0 hypertension and inflammatory reactions. European Journal of Medical Research, 2024, 29, .

**CITATION REPORT**